Category: Pharma Industry News
Cullinan Oncology to sell Cullinan Pearl to Taiho Pharmaceutical for $275m
American biopharma company Cullinan Oncology has agreed to sell its subsidiary Cullinan Pearl to Taiho Pharmaceutical, a Japanese specialty pharma company, for $275 million. Cullinan ... Read More
Alkem Labs clears UK MHRA inspection of bioequivalence center in Taloja
Alkem Laboratories Limited (Alkem Labs) revealed that it has cleared an online inspection held by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of ... Read More
Pfizer to acquire Biohaven in $11.6bn deal to gain access to rimegepant
Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting ... Read More
Zydus Lifesciences gets FDA approval for Bortezomib for Injection
Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for ... Read More
Cara Therapeutics, VFMCRP get EC approval for Kapruvia for pruritus
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) said that Kapruvia (difelikefalin) has secured approval from the European Commission (EC) for the treatment ... Read More
Biocon Q4FY22 results : Indian pharma firm net profit down by 6% to Rs 239cr
Biocon Q4FY22 results : Biocon Ltd has reported a net profit of INR 239 crores for the fourth quarter of the fiscal year 2022 (Q4FY22), ... Read More
GSK to acquire US biopharma company Sierra Oncology for $1.9bn
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9 billion (£1.5 billion). As per the terms ... Read More
Dr. Reddy’s Labs launches Posaconazole Delayed-Release Tablets in US
Dr. Reddy’s Laboratories said that it has launched Posaconazole Delayed-Release Tablets, 100 mg, a triazole antifungal drug, in the US market. Posaconazole Delayed-Release Tablets is ... Read More
Halozyme Therapeutics to acquire specialty pharma company Antares Pharma for $960m
Halozyme Therapeutics, a California-based publicly-listed biotech company, has agreed to acquire New Jersey-based specialty pharma company Antares Pharma for around $960 million with an objective ... Read More
BriaCell Therapeutics’ Bria-IMT gets FDA fast track status in breast cancer
BriaCell Therapeutics has secured the fast track status from the US Food and Drug Administration (FDA) for its lead candidate — Bria-IMT for the treatment ... Read More
